06.04.14
Burlington, Mass.-based LeMaitre Vascular Inc., which makes peripheral vascular devices and implants, has closed its underwritten public offering of 1,644,500 shares of its common stock at a price to the public of $7 per share. The shares include 214,500 shares of common stock sold pursuant to the over-allotment option granted by LeMaitre Vascular to the underwriters, which option was exercised in full.
Canaccord Genuity and Stifel acted as joint book-running managers for the proposed offering. Roth Capital Partners, Barrington Research Associates, The Benchmark Company and Brean Capital acted as co-managers.
The net proceeds from the sale of the shares of common stock, after deducting the underwriting discount and the other offering expenses, are expected to be approximately $10.5 million. LeMaitre Vascular intends to use the net proceeds from the offering together with the Company’s existing cash resources for general corporate purposes, including continued development of its products, working capital and capital expenditures, payments under the company’s quarterly dividend program, deferred payments related to prior acquisitions, and to fund potential future acquisitions.
Canaccord Genuity and Stifel acted as joint book-running managers for the proposed offering. Roth Capital Partners, Barrington Research Associates, The Benchmark Company and Brean Capital acted as co-managers.
The net proceeds from the sale of the shares of common stock, after deducting the underwriting discount and the other offering expenses, are expected to be approximately $10.5 million. LeMaitre Vascular intends to use the net proceeds from the offering together with the Company’s existing cash resources for general corporate purposes, including continued development of its products, working capital and capital expenditures, payments under the company’s quarterly dividend program, deferred payments related to prior acquisitions, and to fund potential future acquisitions.